China doubles down on promoting yuan as confidence in U.S. dollar takes a beating

China doubles down on promoting yuan as confidence in U.S. dollar takes a beating


Key Points
  • China is introducing ways to bolster yuan’s usage as confidence in the U.S. dollar falters.
  • Three major Chinese exchanges have allowed certain foreign institutional investors to trade more futures and options contracts listed in mainland China.
  • From expanding investment channels to building digital infrastructure, Beijing has been laying the groundwork to accelerate international use of its currency.



Source

Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Finance

Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more

Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock fell about 13% after unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug. Novo Nordisk said […]

Read More
Rocket Companies shares jump 6% after CEO says mortgage loan volume is surging
Finance

Rocket Companies shares jump 6% after CEO says mortgage loan volume is surging

In this article RKT Follow your favorite stocksCREATE FREE ACCOUNT watch now VIDEO8:4108:41 Rocket Companies CEO: On track to produce the highest mortgage loan production in 4 years Squawk Box Rocket Companies shares jumped on Tuesday after CEO Varun Krishna told CNBC the company was writing a larger amount of mortgage loans. “We’re getting ready […]

Read More
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
Finance

Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more

Check out the companies making headlines before the bell: Palantir — The stock jumped 11% following the AI-powered software provider’s fourth-quarter earnings beat . Palantir reported adjusted earnings of 25 cents per share, versus the 23 cents expected from analysts polled by LSEG. Revenue was $1.41 billion, topping the $1.33 billion consensus estimate. Merck — […]

Read More